

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 8-K

INTROGEN THERAPEUTICS INC
Form 8-K
May 13, 2003

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 13, 2003

Introgen Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

0-21291

74-2704230

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

301 Congress Avenue, Suite 1850, Austin, Texas 78701

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (512) 708-9310

(Former name or former address, if changed since last report)

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

99.1 Press Release dated May 13, 2003.

Item 9. Regulation FD Disclosure.

Edgar Filing: INTROGEN THERAPEUTICS INC - Form 8-K

The press release filed as an exhibit to this report is being furnished under Item 12 (Furnishing of Earnings Releases) as contemplated by SEC Release Nos. 33-8176 and 33-8216.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 13, 2003

INTROGEN THERAPEUTICS, INC

James W. Albrecht, Jr.
Chief Financial Officer

-2-

INDEX TO EXHIBITS

<u>Exhibit Number</u>	<u>Description of Document</u>
99.1	Press Release dated May 13, 2003.
